{"product_id":"ams-vrio-analysis","title":"American Shared Hospital Services (AMS): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs American Shared Hospital Services (AMS)'s current market position truly defensible? This VRIO analysis cuts straight to the core, rigorously testing whether their key resources are Valuable, Rare, Inimitable, and Organized for sustained competitive advantage. Uncover the definitive verdict on their strengths - and potential blind spots - by reading the full breakdown below.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAmerican Shared Hospital Services (AMS) - VRIO Analysis: Dual Revenue Stream Model (Leasing \u0026amp; Direct Care)\n\u003c\/h2\u003e\n\u003cp\u003eYou're looking at American Shared Hospital Services (AMS) and seeing a company trying to balance two very different business models: owning and leasing expensive radiation equipment, and actually running the treatment centers themselves. The key takeaway here is that the shift toward direct care is accelerating, which is boosting margins but also changing the risk profile.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e This dual approach is definitely valuable because it provides revenue diversification. When equipment leasing gets tight - like the 5.3% drop in leasing revenue in Q3 2025 - the direct care side can pick up the slack. Honestly, the direct patient services segment is where the action is; it hit 56% of total sales in Q3 2025, up from 53% the prior year, and that segment grew 9.4% period over period to $4.0 million in revenue. It’s a smart hedge against the cyclical nature of equipment contracts.\u003c\/p\u003e\n\u003cp\u003eHere’s a quick look at the Q3 2025 segment performance:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eEquipment Leasing\u003c\/td\u003e\n\u003ctd\u003eDirect Patient Care\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeriod-over-Period Change\u003c\/td\u003e\n\u003ctd\u003eDown \u003cstrong\u003e5.3%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eUp \u003cstrong\u003e9.4%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e% of Total Revenue (Q3 2025)\u003c\/td\u003e\n\u003ctd\u003eApprox. 43%\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e56%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e This model is only moderately rare. Plenty of competitors focus on one or the other - either pure-play leasing or owning a chain of clinics. But having both scaled successfully, where direct care is now the majority revenue driver, isn't something every competitor has managed to pull off. It takes a specific operational skill set to manage both high-capital asset deployment and high-touch patient services.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Imitating this is costly and time-consuming, which is good for AMS. The leasing side requires massive upfront capital for assets like the Gamma Knife systems. The direct care expansion, though, involves navigating complex state and international regulatory hurdles, plus building out physician networks. If a competitor wanted to match the 36.5% growth in direct care revenue seen over the first nine months of 2025, they’d face significant regulatory lag time.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e AMS seems organized to exploit this structure, but the results show they are still actively managing the transition. The 9.4% growth in direct care revenue in Q3 2025 shows they are executing on their strategy to lean into services. However, the fact that leasing revenue is shrinking - down to $3.1 million in Q3 2025 from $3.3 million in Q3 2024 - means the organization needs to keep driving service expansion to offset the decline. The improvement in gross margin to 22.1% in Q3 2025, up 15.8% from Q3 2024, suggests better operational leverage is starting to kick in.\u003c\/p\u003e\n\u003cp\u003eHere are the organizational strengths supporting this model:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eActive management of new centers in Mexico.\u003c\/li\u003e\n\u003cli\u003eSecured a 10-year extension with an existing health system.\u003c\/li\u003e\n\u003cli\u003eNarrowed Q3 2025 net loss by 91.8% year-over-year.\u003c\/li\u003e\n\u003cli\u003eStrong 42.3% growth in Adjusted EBITDA for Q3 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Right now, I’d call this a temporary advantage. The direct care segment is clearly the growth engine, but the leasing side is contracting due to factors like contract expirations. The advantage lies in the potential for sustained advantage if they can stabilize the leasing base while continuing the high-margin service growth. If onboarding new centers like the one planned for Guadalajara in Q2 2026 takes longer than expected, churn risk on the leasing side rises.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAmerican Shared Hospital Services (AMS) - VRIO Analysis: Expertise in Stereotactic Radiosurgery and Gamma Knife Technology\n\u003c\/h2\u003e\n\u003cp\u003e\nAMS's core competency centers on specialized, high-precision radiation technology deployment and management.\n\u003c\/p\u003e\n\n\u003ch3\u003eValue: Core competency in high-precision cancer treatment delivery, which is critical for securing high-value hospital contracts and driving patient volumes.\u003c\/h3\u003e\n\u003cp\u003e\nThe expertise supports revenue generation across segments. Direct Patient Services Revenue for the first nine months of 2025 was \u003cstrong\u003e$10.7 million\u003c\/strong\u003e, an increase of \u003cstrong\u003e36.5%\u003c\/strong\u003e year-over-year, driven by new centers like Puebla, Mexico. The leasing segment revenue was \u003cstrong\u003e$9.7 million\u003c\/strong\u003e for the same period. The company secured a \u003cstrong\u003e10-year extension\u003c\/strong\u003e with an existing health system for their latest model Gamma Knife system, Esprit.\n\u003c\/p\u003e\n\n\u003ch3\u003eRarity: Rare; deep, specialized clinical and technical knowledge for these specific, high-end devices is not easily replicated.\u003c\/h3\u003e\n\u003cp\u003e\nAMS is a leading global provider of Gamma Knife radiosurgery equipment. As of December 31, 2021, the company had \u003cstrong\u003e115\u003c\/strong\u003e operating Gamma Knife units in the United States and \u003cstrong\u003e2\u003c\/strong\u003e in South America. The U.S. market share for Gamma Knife radiosurgery equipment is approximately \u003cstrong\u003e11%\u003c\/strong\u003e.\n\u003c\/p\u003e\n\n\u003ch3\u003eImitability: Very difficult to imitate due to the tacit knowledge embedded in long-term clinical teams and service contracts.\u003c\/h3\u003e\n\u003cp\u003e\nThe specialized nature of the technology and long-term partnership structures create high barriers. The company's subsidiary, GK Financing, holds an \u003cstrong\u003e81%\u003c\/strong\u003e ownership stake in a partnership with Elekta for Gamma Knife products.\n\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eFY 2023\u003c\/td\u003e\n\u003ctd\u003eFY 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$21.33 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$28.34 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$610,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.186 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLeasing Segment Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17.772 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$15.629 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eOrganization: Highly organized, as evidenced by the expected startup of a new Esprit Gamma Knife center in Guadalajara late in 2025.\u003c\/h3\u003e\n\u003cp\u003e\nOrganizational focus is on international expansion and technology upgrades.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eJoint Venture agreement signed in July 2024 for Guadalajara facility.\u003c\/li\u003e\n\u003cli\u003eThe new Joint Venture will hold \u003cstrong\u003e70%\u003c\/strong\u003e ownership for AMS.\u003c\/li\u003e\n\u003cli\u003eThe center will upgrade to an \u003cstrong\u003eEsprit\u003c\/strong\u003e system.\u003c\/li\u003e\n\u003cli\u003eExpected startup for the Guadalajara center is the \u003cstrong\u003esecond quarter of 2026\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage: Sustained; this specialized, high-barrier-to-entry clinical expertise is a long-term moat.\u003c\/h3\u003e\n\u003cp\u003e\nSustained advantage is supported by recent performance metrics showing operational leverage despite segment revenue shifts.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ3 2025 EBITDA was \u003cstrong\u003e$1.94 million\u003c\/strong\u003e, up \u003cstrong\u003e42.3%\u003c\/strong\u003e from Q3 2024's \u003cstrong\u003e$1.37 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Net Loss decreased \u003cstrong\u003e91.8%\u003c\/strong\u003e to \u003cstrong\u003e$17,000\u003c\/strong\u003e from a loss of \u003cstrong\u003e$207,000\u003c\/strong\u003e in Q3 2024.\u003c\/li\u003e\n\u003cli\u003eDirect patient care services revenue represented \u003cstrong\u003e56%\u003c\/strong\u003e of total sales in Q3 2025, up from \u003cstrong\u003e53%\u003c\/strong\u003e in the prior year period.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAmerican Shared Hospital Services (AMS) - VRIO Analysis: Growing International Operational Footprint (Mexico)\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003eGrowing International Operational Footprint (Mexico)\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eValue:\u003c\/strong\u003e Access to new, potentially less saturated markets, as seen by the increased procedures at the Puebla center driving Q3 2025 direct revenue growth. Direct patient care services revenue was \u003cstrong\u003e$4.0 million\u003c\/strong\u003e for Q3 2025, an increase of \u003cstrong\u003e9.4%\u003c\/strong\u003e period over period. The new radiation therapy treatment center in Puebla, Mexico, showed a \u003cstrong\u003e263%\u003c\/strong\u003e annual revenue growth in Q3 2025.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderately rare; successfully navigating international healthcare regulations and establishing new centers is a unique skill set for this firm. The Retail segment includes facilities in Peru and Ecuador.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; requires capital, local relationships, and regulatory navigation that competitors may lack. Management explicitly cited international expansion as a growth driver, with a planned Guadalajara, Mexico center startup in the \u003cstrong\u003esecond quarter of 2026\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eOrganization:\u003c\/strong\u003e Organized to exploit this, with management explicitly citing international expansion as a growth driver. The direct patient care services segment represented \u003cstrong\u003e56%\u003c\/strong\u003e of total sales in Q3 2025, up from \u003cstrong\u003e53%\u003c\/strong\u003e in the prior year period.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; success in one region can attract fast followers if the initial setup is not protected by unique local partnerships.\n\u003c\/p\u003e\n\u003cp\u003e\nKey financial metrics supporting the international segment's contribution:\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ3 2025 Amount\u003c\/th\u003e\n\u003cth\u003eYear-over-Year Change (Q3)\u003c\/th\u003e\n\u003cth\u003eNine Months 2025 Amount\u003c\/th\u003e\n\u003cth\u003eYear-over-Year Change (Nine Months)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect Patient Care Services Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+9.4%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e+36.5%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect Patient Care Services Revenue as % of Total Sales\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e56%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncrease from \u003cstrong\u003e53%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePuebla Center Annual Revenue Growth\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e263%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\nFurther details on segment performance:\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFor the nine months ended September 30, 2025, revenue from direct patient care services was \u003cstrong\u003e$10.7 million\u003c\/strong\u003e compared to \u003cstrong\u003e$7.8 million\u003c\/strong\u003e in the same period in the prior year.\u003c\/li\u003e\n\u003cli\u003eEquipment leasing segment revenue decreased \u003cstrong\u003e5.3%\u003c\/strong\u003e to \u003cstrong\u003e$3.1 million\u003c\/strong\u003e for Q3 2025 compared to \u003cstrong\u003e$3.3 million\u003c\/strong\u003e in the prior year period.\u003c\/li\u003e\n\u003cli\u003eFor the first nine months of 2025, total revenue increased \u003cstrong\u003e5.6%\u003c\/strong\u003e to \u003cstrong\u003e$20.4 million\u003c\/strong\u003e compared to \u003cstrong\u003e$19.3 million\u003c\/strong\u003e for the first nine months of 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAmerican Shared Hospital Services (AMS) - VRIO Analysis: Strategic Regional Expansion in US (Rhode Island)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eStrategic Regional Expansion in US (Rhode Island)\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eDeepening market penetration in a specific US region, securing future revenue through new Certificate of Need approvals for centers in Bristol and Johnston. The acquisition of 60% majority interest in three existing radiation therapy facilities in Rhode Island contributed to a $3.79 million bargain purchase gain in FY 2024. Direct Patient Services Revenue increased 253.4% year-over-year in FY 2024, reaching $12,556,000, largely driven by these Rhode Island centers.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eRare in the sense of targeted, successful Certificate of Need acquisition and execution within a concentrated area. The Johnston Proton Beam Radiation Treatment (PBRT) facility, once operational, will be one of only two PBRT Systems in operation in the Northeast, strategically positioned between the New York City and Boston markets.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eModerately difficult; CON processes are jurisdiction-specific and require dedicated regulatory effort. The Johnston PBRT facility received CON approval in December 2024, following a unanimous recommendation by the Health Service Council. The expected time to treat first patients for the Johnston facility is 36 to 39 months from the approval date.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eOrganized, as the company has secured approvals and is focused on expanding this footprint for long-term growth. The company has added senior management with expertise in development, acquisition, and operation of free-standing radiation therapy facilities.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eTemporary; once the new centers are fully operational, the advantage will normalize unless they secure exclusive regional rights. The company is focused on operational efficiencies and partnerships, such as with the Brown University Health System for staffing.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eKey Financial and Operational Metrics Related to Rhode Island Expansion:\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003ePeriod\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY 2024 Total Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$28,340,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eYear ended December 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY 2024 Direct Patient Services Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12,556,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncrease of \u003cstrong\u003e253.4%\u003c\/strong\u003e from 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ4 2024 Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$9,069,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncrease of \u003cstrong\u003e59.2%\u003c\/strong\u003e year-over-year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBargain Purchase Gain from RI Acquisition\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3,794,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFY 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRI Facilities Acquired (Ownership Stake)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eThree\u003c\/strong\u003e (\u003cstrong\u003e60%\u003c\/strong\u003e majority interest)\u003c\/td\u003e\n\u003ctd\u003eAcquisition closed May 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew CON Approved - Bristol Center\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eOne\u003c\/strong\u003e (Fourth radiation therapy center)\u003c\/td\u003e\n\u003ctd\u003eApril 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew CON Approved - Johnston Center\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eOne\u003c\/strong\u003e (Proton Beam Radiation Treatment)\u003c\/td\u003e\n\u003ctd\u003eDecember 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganizational Focus Areas for Expansion:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSecured Certificate of Need approvals for two additional facilities in Rhode Island.\u003c\/li\u003e\n\u003cli\u003eThe Johnston PBRT facility is expected to begin treating patients in 36 – 39 months from December 2024.\u003c\/li\u003e\n\u003cli\u003eThe company is leveraging partnerships, including with the Brown University Health System for radiation oncologist staffing.\u003c\/li\u003e\n\u003cli\u003eThe RI acquisition expanded the US business model from technology supplier to direct provider of cancer care.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAmerican Shared Hospital Services (AMS) - VRIO Analysis: Established Health System Partnership Network\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eEstablished Health System Partnership Network\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides a stable pipeline for both equipment leasing and direct service contracts, underpinning the business's foundation. Direct patient care services revenue for Q3 2025 was $4.0 million, an increase of 9.4% period over period, accounting for 56% of total sales.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Common in healthcare, but the quality and longevity of their specific, multi-decade relationships are likely rare. The company was founded in 1980.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Difficult; built on trust, proven performance, and relationship capital that takes years to develop.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Organized, demonstrated by the announcement of a 10-year extension with an existing health system in Q3 2025.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; deep, trusted relationships are a powerful, hard-to-break barrier.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ3 2025 Amount\u003c\/th\u003e\n\u003cth\u003eYear-over-Year Change (Q3)\u003c\/th\u003e\n\u003cth\u003eNine Months 2025 Amount\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2.5%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$20.4 million\u003c\/strong\u003e (\u003cstrong\u003e5.6%\u003c\/strong\u003e increase)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.94 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e42.3%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect Patient Services Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e9.4%\u003c\/strong\u003e increase\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$10.7 million\u003c\/strong\u003e (\u003cstrong\u003e36.5%\u003c\/strong\u003e increase)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e22.1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e15.8%\u003c\/strong\u003e increase (in dollars: $1.6 million)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss Attributable to AMS\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecreased by \u003cstrong\u003e91.8%\u003c\/strong\u003e (from $207,000 loss in Q3 2024)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$0.9 million\u003c\/strong\u003e loss\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eThe company is focused on strategic initiatives to enhance efficiency and leverage economies of scale.\u003c\/li\u003e\n\u003cli\u003eAMS is focused beyond its traditional medical equipment leasing model to a direct provider of radiation therapy treatment services.\u003c\/li\u003e\n\u003cli\u003eThe company has Certificate of Need approvals for expansion in Bristol, Rhode Island, and a proton beam radiation therapy treatment center in Johnston, Rhode Island.\u003c\/li\u003e\n\u003cli\u003eExpected startup of a new Esprit system in Guadalajara, Mexico, in the second quarter of 2026.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eAmerican Shared Hospital Services (AMS) - VRIO Analysis: Operational Efficiency Gains (Margin Improvement)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Directly translates to profitability; gross margin improved to \u003cstrong\u003e22.1%\u003c\/strong\u003e in Q3 2025, and Adjusted EBITDA rose \u003cstrong\u003e42.3%\u003c\/strong\u003e year-over-year to \u003cstrong\u003e$1.94 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ3 2025\u003c\/th\u003e\n\u003cth\u003eQ3 2024\u003c\/th\u003e\n\u003cth\u003eChange\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin Percentage\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e22.1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e19.6%\u003c\/td\u003e\n\u003ctd\u003eImproved\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin Amount\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$1.4 million\u003c\/td\u003e\n\u003ctd\u003eIncreased \u003cstrong\u003e15.8%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdjusted EBITDA\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.94 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$1.37 million\u003c\/td\u003e\n\u003ctd\u003eIncreased \u003cstrong\u003e42.3%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Loss Attributable\u003c\/td\u003e\n\u003ctd\u003eLoss of \u003cstrong\u003e$17 thousand\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eLoss of $207 thousand\u003c\/td\u003e\n\u003ctd\u003eDecreased \u003cstrong\u003e91.8%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Rare, especially when coupled with revenue growth; many firms struggle to improve margins while expanding.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderately difficult; requires process re-engineering and disciplined cost control that is hard to copy quickly.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Clearly organized around this, as management is focused on strategic initiatives to enhance efficiency and leverage economies of scale.\u003c\/p\u003e\n\u003cp\u003eKey operational context supporting margin improvement:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDirect patient services revenue increased \u003cstrong\u003e9.4%\u003c\/strong\u003e period over period in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eDirect patient care services accounted for \u003cstrong\u003e56%\u003c\/strong\u003e of total sales in Q3 2025.\u003c\/li\u003e\n\u003cli\u003eThe company is executing on a strategy moving beyond the traditional medical equipment leasing model.\u003c\/li\u003e\n\u003cli\u003eOperating loss narrowed with a \u003cstrong\u003e92%\u003c\/strong\u003e improvement.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; efficiency gains can often be matched by competitors who adopt similar best practices over time.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAmerican Shared Hospital Services (AMS) - VRIO Analysis: Advanced Radiation Therapy Service Portfolio (PBRT, IMRT\/IGRT)\n\u003c\/h2\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eAllows the company to offer a full spectrum of modern cancer care modalities, making them a one-stop solution for hospital partners.\u003c\/p\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eModerately rare; offering the full suite, including the complex Proton Beam Radiation Therapy (PBRT), is a high bar.\u003c\/p\u003e\n\u003cp\u003eAMS leases \u003cstrong\u003eone\u003c\/strong\u003e proton beam radiation therapy (PBRT) system and \u003cstrong\u003enine\u003c\/strong\u003e Gamma Knife systems.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eVery difficult; requires massive capital investment and specialized clinical staff for each modality.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eFY 2024 Amount\u003c\/th\u003e\n\u003cth\u003eFY 2023 Amount\u003c\/th\u003e\n\u003cth\u003eChange\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Proton Therapy Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$9,952,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10,133,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecreased \u003cstrong\u003e1.8%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProton Therapy Treatments\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5,139\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5,369\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecreased \u003cstrong\u003e4.3%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLeasing Segment Revenue (Includes PBRT)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$15,629,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17,772,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecreased \u003cstrong\u003e12.1%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eOrganized to support this, though the leasing segment revenue from PBRT declined, indicating a strategic focus shift rather than a technology failure.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eLeasing segment revenue, including equipment sales, was \u003cstrong\u003e$4,320,000\u003c\/strong\u003e in Q4 2024 compared to \u003cstrong\u003e$4,785,000\u003c\/strong\u003e in Q4 2023.\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Revenue from the medical equipment leasing segment decreased \u003cstrong\u003e5.3%\u003c\/strong\u003e to \u003cstrong\u003e$3.1 million\u003c\/strong\u003e compared to \u003cstrong\u003e$3.3 million\u003c\/strong\u003e in the prior year period due to lower PBRT volumes.\u003c\/li\u003e\n\u003cli\u003eDirect patient services revenue increased to \u003cstrong\u003e$12,556,000\u003c\/strong\u003e for FY 2024 from \u003cstrong\u003e$3,553,000\u003c\/strong\u003e in 2023.\u003c\/li\u003e\n\u003cli\u003eThe company recognized a material weakness in its internal controls over financial reporting due to an insufficient number of experienced personnel.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained; the capital and expertise required to maintain this broad, advanced portfolio create a high barrier.\u003c\/p\u003e\n\u003cp\u003eThe company is pursuing Certificate of Need approvals for a proton beam radiation treatment center in Johnston, Rhode Island.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eAmerican Shared Hospital Services (AMS) - VRIO Analysis: Management Focus on Direct Patient Services Growth\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eManagement Focus on Direct Patient Services Growth\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThis strategic focus is driving the financial turnaround, with direct patient services revenue increasing \u003cstrong\u003e9.4%\u003c\/strong\u003e period over period in Q3 2025 and reducing the net loss by \u003cstrong\u003e91.8%\u003c\/strong\u003e to just \u003cstrong\u003e\\$17,000\u003c\/strong\u003e (from a loss of \u003cstrong\u003e\\$207,000\u003c\/strong\u003e in Q3 2024).\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eDirect Patient Services Revenue (Q3 2025): \u003cstrong\u003e\\$4.0 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eNet Loss Reduction (Q3 2025): \u003cstrong\u003e91.8%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eNet Loss Amount (Q3 2025): \u003cstrong\u003e\\$17,000\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eAdjusted EBITDA (Q3 2025): \u003cstrong\u003e\\$1.94 million\u003c\/strong\u003e, an increase of \u003cstrong\u003e42.3%\u003c\/strong\u003e year-over-year\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eRare; the commitment to pivot away from a legacy model, even when it means short-term leasing revenue dips, is a rare strategic discipline.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eSegment\u003c\/td\u003e\n\u003ctd\u003eQ3 2025 Revenue\u003c\/td\u003e\n\u003ctd\u003ePeriod Over Period Change\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect Patient Services\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$4.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIncrease of \u003cstrong\u003e9.4%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical Equipment Leasing\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$3.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecrease of \u003cstrong\u003e5.3%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eDifficult; it requires strong alignment from the board and executive team, which is often lacking in established firms.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eDirect Patient Care Services Segment Share of Total Sales (Q3 2025): \u003cstrong\u003e56%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eDirect Patient Care Services Revenue (Nine Months Ended Sept 30, 2025): \u003cstrong\u003e\\$10.7 million\u003c\/strong\u003e, up \u003cstrong\u003e36.5%\u003c\/strong\u003e year-over-year\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eHighly organized around this, as the CFO explicitly stated the focus is moving beyond the traditional leasing model.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cp\u003eScott Frech, Chief Financial Officer, stated the momentum continues to build, as the company executes on its growth strategy and focuses \u003cstrong\u003ebeyond our traditional medical equipment leasing model to a direct provider of radiation therapy treatment services to cancer patients\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eSustained; a clear, executed strategic direction is a powerful organizational capability.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eGross Margin (Q3 2025): \u003cstrong\u003e22.1%\u003c\/strong\u003e, an increase of \u003cstrong\u003e15.8%\u003c\/strong\u003e period over period\u003c\/li\u003e\n\u003cli\u003eCash and Equivalents (Sept 30, 2025): \u003cstrong\u003e\\$5.3 million\u003c\/strong\u003e after \u003cstrong\u003e\\$7.5 million\u003c\/strong\u003e CapEx\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\n\u003cbr\u003e\u003ch2\u003eAmerican Shared Hospital Services (AMS) - VRIO Analysis: Experience in Equipment Financing and Leasing\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eExperience in Equipment Financing and Leasing\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides a historical foundation and a unique value proposition to hospitals needing capital for high-cost equipment like Gamma Knife. The Company is the leader in Gamma Knife financing, with numerous units operating at prominent hospitals and medical centers across the United States.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Not rare in the broader finance world, but their specific experience structuring complex, long-term medical equipment leases is specialized. The Company offers innovative financing solutions including: Minimal capital requirements; No minimum volume requirements; No fixed monthly payments; No technological obsolescence.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Moderately easy; financial structures can be reverse-engineered, but the risk appetite and track record are harder to match. The Company has over 100 years of industry experience across its team.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Organized, but this segment is intentionally shrinking, suggesting the organization is prioritizing the direct care model over leveraging this older capability. Revenue from the medical equipment leasing segment decreased 5.3% to $3.1 million for Q3 2025 compared to $3.3 million in the prior year period due to lower PBRT volumes. Direct patient services revenue made up 56% of total revenue for the third quarter of 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; it’s a legacy strength that is currently being de-emphasized in favor of direct care.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eFinance: Sensitivity Analysis on Q3 2025 Gross Margin\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003eThe analysis is based on the reported Q3 2025 Gross Margin of 22.1% and Q3 2025 PBRT volume data.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eBase Case (Q3 2025 Reported)\u003c\/td\u003e\n\u003ctd\u003eScenario: 5% Drop in PBRT Volumes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e22.1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eRequires further calculation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$7.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eHypothetical reduction of $0.105 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBRT Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eHypothetical reduction of $0.105 million (5% of $2.1M)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePBRT Fractions\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,150\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eHypothetical reduction of 57.5 (5% of 1,150)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Profit\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$1.5912 million\u003c\/strong\u003e ($7.2M  22.1%)\u003c\/td\u003e\n\u003ctd\u003eRequires assumption on margin mix\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe impact on the overall gross margin by next Wednesday cannot be definitively calculated without knowing the gross margin contribution of the PBRT sub-segment relative to the total gross profit, especially given the segment margin differences.\u003c\/p\u003e\n\n\u003cp\u003eRelevant Financial Data Points:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ3 2025 Gross Margin: \u003cstrong\u003e22.1%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Gross Profit: \u003cstrong\u003e$1.6 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Total Revenue: \u003cstrong\u003e$7.2 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eQ3 2025 PBRT Revenue: \u003cstrong\u003e$2.1 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eQ3 2025 PBRT Fractions: \u003cstrong\u003e1,150\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Direct Patient Services Revenue: \u003cstrong\u003e$4.0 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Net Loss: \u003cstrong\u003e$17,000\u003c\/strong\u003e or \u003cstrong\u003e$55,000\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eQ3 2025 Adjusted EBITDA: \u003cstrong\u003e$1.94 million\u003c\/strong\u003e or \u003cstrong\u003e$1.9 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516111839381,"sku":"ams-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/ams-vrio-analysis.png?v=1740145554","url":"https:\/\/dcf-model.com\/fr\/products\/ams-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}